Jeffrey Hung
Stock Analyst at Morgan Stanley
(2.10)
# 2,801
Out of 4,883 analysts
207
Total ratings
36.79%
Success rate
-6.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Maintains: Overweight | $52 → $56 | $26.69 | +109.82% | 4 | Jun 17, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Equal-Weight | $20 → $24 | $21.23 | +13.05% | 25 | May 20, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Overweight | $25 → $20 | $3.96 | +405.05% | 3 | May 19, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $64 → $65 | $39.53 | +64.43% | 8 | May 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $183 → $166 | $110.09 | +50.79% | 6 | May 7, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Equal-Weight | $15 → $17 | $7.47 | +127.58% | 5 | May 6, 2025 | |
| ENGN enGene Holdings | Maintains: Overweight | $37 → $34 | $3.95 | +760.76% | 3 | Mar 11, 2025 | |
| RYTM Rhythm Pharmaceuticals | Assumes: Overweight | $72 | $66.85 | +7.71% | 11 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Assumes: Overweight | $67 → $70 | $49.25 | +42.15% | 11 | Mar 7, 2025 | |
| NBIX Neurocrine Biosciences | Assumes: Overweight | $185 → $150 | $129.53 | +15.80% | 26 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $4 | $1.45 | +175.86% | 3 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $53.10 | +60.08% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $38 → $35 | $7.82 | +347.57% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $13.72 | +96.86% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $5 | $4.25 | +17.65% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $70 → $67 | $34.31 | +95.28% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $17 → $12 | $5.95 | +101.85% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $5.68 | +516.20% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $70 | $29.55 | +136.89% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $0.81 | +392.61% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $13 → $4 | $7.98 | -49.87% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $0.74 | +440.83% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $3.58 | +291.06% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $2.82 | +77.62% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $1.17 | +156.41% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $1.45 | +865.52% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $2.03 | +392.61% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $44.30 | -50.34% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $14.76 | +906.10% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $1.70 | +3,429.41% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $3.21 | +86.92% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $58 → $54 | $0.44 | +12,200.68% | 6 | May 8, 2020 |
CG Oncology
Jun 17, 2025
Maintains: Overweight
Price Target: $52 → $56
Current: $26.69
Upside: +109.82%
ACADIA Pharmaceuticals
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $21.23
Upside: +13.05%
Contineum Therapeutics
May 19, 2025
Maintains: Overweight
Price Target: $25 → $20
Current: $3.96
Upside: +405.05%
Ultragenyx Pharmaceutical
May 9, 2025
Maintains: Overweight
Price Target: $64 → $65
Current: $39.53
Upside: +64.43%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Overweight
Price Target: $183 → $166
Current: $110.09
Upside: +50.79%
Bicycle Therapeutics
May 6, 2025
Maintains: Equal-Weight
Price Target: $15 → $17
Current: $7.47
Upside: +127.58%
enGene Holdings
Mar 11, 2025
Maintains: Overweight
Price Target: $37 → $34
Current: $3.95
Upside: +760.76%
Rhythm Pharmaceuticals
Mar 7, 2025
Assumes: Overweight
Price Target: $72
Current: $66.85
Upside: +7.71%
PTC Therapeutics
Mar 7, 2025
Assumes: Overweight
Price Target: $67 → $70
Current: $49.25
Upside: +42.15%
Neurocrine Biosciences
Mar 7, 2025
Assumes: Overweight
Price Target: $185 → $150
Current: $129.53
Upside: +15.80%
Mar 7, 2025
Assumes: Overweight
Price Target: $4
Current: $1.45
Upside: +175.86%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $53.10
Upside: +60.08%
Mar 7, 2025
Assumes: Overweight
Price Target: $38 → $35
Current: $7.82
Upside: +347.57%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $13.72
Upside: +96.86%
Mar 7, 2025
Assumes: Underweight
Price Target: $5
Current: $4.25
Upside: +17.65%
Feb 13, 2025
Upgrades: Overweight
Price Target: $70 → $67
Current: $34.31
Upside: +95.28%
Dec 13, 2024
Downgrades: Equal-Weight
Price Target: $17 → $12
Current: $5.95
Upside: +101.85%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $5.68
Upside: +516.20%
May 23, 2024
Maintains: Overweight
Price Target: $50 → $70
Current: $29.55
Upside: +136.89%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $0.81
Upside: +392.61%
Dec 19, 2023
Downgrades: Underweight
Price Target: $13 → $4
Current: $7.98
Upside: -49.87%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $0.74
Upside: +440.83%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $3.58
Upside: +291.06%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $2.82
Upside: +77.62%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $1.17
Upside: +156.41%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $1.45
Upside: +865.52%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $2.03
Upside: +392.61%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $44.30
Upside: -50.34%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $14.76
Upside: +906.10%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $1.70
Upside: +3,429.41%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $3.21
Upside: +86.92%
May 8, 2020
Maintains: Overweight
Price Target: $58 → $54
Current: $0.44
Upside: +12,200.68%